Vaxcyte Inc. (PCVX) is being touted as a hidden gem that could deliver outsized returns for those willing to hold through the inevitable ups and downs of a biotech play. The company’s focus on rare‑disease therapeutics places it in a niche that has historically attracted high valuation multiples once a product reaches market approval. If the firm can navigate the regulatory hurdles and secure commercial partnerships, the upside could be significant—hence the “multibagger” label.
From a retail perspective, Vaxcyte is a reminder that diversification can extend beyond crypto and traditional equities. While the current crypto market is in a state of extreme fear (BTC down 0.46% and ETH up 1.1% amid whale activity), the biotech sector offers a different risk‑reward profile